<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="952">
  <stage>Registered</stage>
  <submitdate>28/10/2005</submitdate>
  <approvaldate>28/10/2005</approvaldate>
  <nctid>NCT00247273</nctid>
  <trial_identification>
    <studytitle>A Study of Monthly Risedronate for Osteoporosis</studytitle>
    <scientifictitle>A Phase III, Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly With 5 mg Risedronate Daily in the Treatment of Postmenopausal Osteoporosis (PMO)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EFC6062 AND HMRF004M/3001</secondaryid>
    <secondaryid>2005032</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Postmenopausal Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - risedronate
Treatment: drugs - risedronate

Active Comparator: 1 - 5 mg risedronate, once daily for 2 years

Experimental: 2 - 150 mg risedronate taken once a month for 2 years


Treatment: drugs: risedronate
tablet, 5 mg risedronate, once a day for 2 years

Treatment: drugs: risedronate
oral, 150 mg risedronate, once a month for 2 years

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12-Endpoint in Women With Postmenopausal Osteoporosis, Primary Efficacy Population - BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).</outcome>
      <timepoint>Baseline to Month 12 - Endpoint</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population - BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</outcome>
      <timepoint>Baseline to Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Lumbar Spine BMD at Month 12, ITT Population - BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</outcome>
      <timepoint>Baseline to Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Lumbar Spine BMD at Month 24-Endpoint, Endpoint Population (Month 24) - BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 24).</outcome>
      <timepoint>Baseline to Month 24 - Endpoint</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population - BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Lumbar Spine BMD at Month 24, ITT Population - BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment.</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Urine Type-1 Collagen Cross-linked-N-telopeptide Corrected for Creatinine Clearance (NTX/Cr) at Month 6, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24. nmol BCE / mmol Creatinine = nanomoles bone collagen equivalents / millimoles Creatinine</outcome>
      <timepoint>Baseline to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Urine NTX/Cr at Month 6, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</outcome>
      <timepoint>Baseline to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Urine NTX/Cr at Month 24, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Urine NTX/Cr at Month 24, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay) for NTX and colorimetric assay for creatinine. Patient collected second urine voided between 6 and 9 am from day of clinic visit and day before clinic visit at Months 3, 6, 12 &amp; 24.</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Type-1 Collagen Cross-linked C-telopeptide (CTX) at Month 6, ITT Population - ng / mL = nanograms / milliliter. Assayed by electrochemiluminescent immunoassay.</outcome>
      <timepoint>Baseline to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum CTX at Month 6, ITT Population - Assayed by electrochemiluminescent immunoassay.</outcome>
      <timepoint>Baseline to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum CTX at Month 24, ITT Population - Assayed by electrochemiluminescent immunoassay.</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum CTX at Month 24, ITT Population - Assayed by electrochemiluminescent immunoassay.</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum Bone-specific Alkaline Phosphatase (BAP) at Month 6, ITT Population - ug / L = micrograms per liter, Assayed by ELISA (enzyme-linked immunosorbent assay)</outcome>
      <timepoint>Baseline to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum BAP at Month 6, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay)</outcome>
      <timepoint>Baseline to Month 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Serum BAP at Month 24, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay)</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent Change From Baseline in Serum BAP at Month 24, ITT Population - Assayed by ELISA (enzyme-linked immunosorbent assay)</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With New Vertebral Fracture at Month 12, ITT Population - At least 1 new fractured vertebra</outcome>
      <timepoint>Baseline to Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With New Vertebral Fracture at Month 24, ITT Population - At least 1 new fractured vertebra</outcome>
      <timepoint>Baseline to Month 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female: 50 years of age or older

          -  &gt;5 years since last menses natural or surgical

          -  have lumbar spine BMD (bone mineral density) more that 2.5 standard deviations (SD)
             below the young adult mean, or have 1-spine BMD more than 2.0 SD below the young adult
             female mean value and also have at least one prevalent vertebral body fracture</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia

          -  BMI (body mass index) &gt;32 kg/m^2

          -  use of medications within 3 months of starting study drug that impact bone metabolism
             such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and
             parathyroid hormone

          -  hypocalcemia or hypercalcemia of any cause

          -  markedly abnormal clinical laboratory measurements that are assessed as clinically
             significant by the investigator</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1294</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Geelong</hospital>
    <hospital>Research Site - Heidelberg, Victoria</hospital>
    <hospital>Research Site - Saint Leonards</hospital>
    <postcode> - Geelong</postcode>
    <postcode> - Heidelberg, Victoria</postcode>
    <postcode> - Saint Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Capital Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mont Godinne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Calgary</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Montreal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Sainte Foy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatoon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Parnu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Orleans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre Les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Balatonfured</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Miskolc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nagykanizs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Paradis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Trondheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Warner Chilcott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Sanofi</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as
      compared to the standard daily dosing regimen of risedronate 5 mg daily.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00247273</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sal Bartelmo, MD</name>
      <address>P&amp;G</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>